Abstracts surgical procedures among younger patients for the management of DD. METHODS: Using a nationwide commercial claims database, a retrospective cohort was identified who had undergone LC (n = 2095) or OC (n = 5971) between 4 th quarter, 2005 through 1 st quarter, 2009. 2000 U.S. Census data was used to calculate age-adjusted temporal trends in the overall surgical procedure and logistic regression was used to determine the time trends in each surgical procedure, adjusting for age, gender, and the type of benefit plan. RESULTS: A total of 8,066 surgical procedures were performed during the study period (mean age = 53 ± 11, 55.7% Male). Quarterly mean number of surgical procedures(LC+OC) performed was 576 (SD = 39) and the annual mean number of LC+OC from 2006 to 2008 was 2297 (SD = 107). Quarterly agestandardized surgical procedures(LC+OC) for DD declined by 9.26% for patients younger than 45, whereas overall surgical rate increased by 3.2% for older patients. The odds of having a LC over OC declined by 8% each consecutive quarter (95% CI 0.91, 0.93) while controlling for other covariates. CONCLUSIONS: Data suggest that there was a slight decline over time in surgical procedures for younger patients. The reasons for the decline in surgical procedures for younger patients may be due to recent studies suggesting that DD is not more aggressive in younger patients as initially reported, and that the conservative medical treatment may be more appropriate with this population. 1950-1955. Longitudinal data across five years demonstrated increasing diagnosis rates with additional years of observation, according to a log function. Modeled for 10 years of observation, total diagnosed prevalence was estimated at 0.29% (R2 = 0.99); peak prevalence was 1.35% for males and 0.64% for females for those born in the early 1950s. CONCLU-SIONS: In each year examined, the claims-based prevalence of an HCV diagnosis was about 10% of the NHANES estimated prevalence (0.12% vs. 1.3%). Although diagnosed HCV prevalence increased with years of observation, the 10-year modeled diagnosis prevalence was only 22% of NHANES estimated prevalence. Like in NHANES, peak prevalence of HCV in claims was observed in patients born in the 1950s. This suggests that many patients have long-standing HCV infection and are at possible risk of decompensation. Further research is warranted to examine whether HCV-related advanced liver disease is more commonly coded in claims data. 4 Covance Market Access Services Inc., Gaithersburg, MD, USA OBJECTIVES: Low persistency for oral 5-ASA drugs is associated with increased risk of relapse of ulcerative colitis(UC) and subsequent costs. We constructed a one-year budget impact model to compare annual all-cause direct incremental costs(IC) of treatment for the health plan(HP) per mild-to-moderate UC patient using oral 5-ASA drugs and associated persistency rates(PRs). METHODS: Assuming a budget holder's perspective for a one-year horizon, the model analyzed the impact of PR on total UC related all-cause direct IC. PRs for 5-ASA drugs(mesalamine CR[CRM] 250mg 7% & 500mg 10%, balsalazide disodium[BD] 10%, olsalazine[OLS] 10%, mesalamine DR[DRM] 9%, multi matrix system mesalamine[MMX] 20%) were derived from published literature. UC patients within the HP were distributed to drugs based on September 2009 market share data and classified as persistent if they refilled within a timeframe of up to twice the duration of their prescription. Annual UC-related pharmacy costs were calculated using net wholesale acquisition cost, and additional allcause direct ICs for patients with/without relapse were cited from published literature. Sensitivity analyses varying net drug costs and PRs were performed to determine impact on health care costs. RESULTS: Average annual all-cause UC costs per patient were: $13,135 CRM-250; $13,065 CRM-500; $12,914 BD; $12,804 OLS, $12,688 DRM; $12,255 MMX. Inpatient costs were lower for MMX($5,667) as compared to market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensitivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, respectively). The primary driver for inpatient cost differences was the frequency of relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC patients) can save $401,000($0.03 per member/month) by switching 50% of UC patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication persistence on reduction of UC relapse and associated health care costs. Health plans may achieve savings by including drugs with high PRs in their formulary.
market leader(DRM;$6,216) and lowest priced drug alternative(OLS;$6,343). Sensitivity analyses indicated higher savings/patient for MMX than DRM($462 vs. $30, respectively). The primary driver for inpatient cost differences was the frequency of relapse reduced by persistency. A health plan with 1 million covered lives(2,300 UC patients) can save $401,000($0.03 per member/month) by switching 50% of UC patients to MMX. CONCLUSIONS: This analysis illustrates the impact of medication persistence on reduction of UC relapse and associated health care costs. Health plans may achieve savings by including drugs with high PRs in their formulary.
PGI10 PATIENT FINANCIAL BURDEN, SURGICAL COSTS AND REIMBURSEMENTS FOR OPEN AND LAPAROSCOPIC COLECTOMY PROCEDURES IN DIVERTICULAR DISEASE
Chung JK, Knight TK, Nichol MB University of Southern California, Los Angeles, CA, USA OBJECTIVES: Colectomy is a standard procedure in complicated colonic diverticular disease (DD) including diverticulosis and diverticulitis. Although laparoscopic colectomy (LC) has demonstrated some clinical advantages over open colectomy (OC), the true financial burden, cost and reimbursement structures between the two surgical procedures remain unclear. The purpose of this study was to compare patient financial burden, direct surgical costs and reimbursements for OC and LC procedures in DD. METHODS: Nationwide commercial claims database from 2003 through 2007 was used to identify 1,614 patients who had undergone OC (n = 1327) or LC (n = 287) for DD. Patient financial burden (defined by out-of-pocket [OOP] costs including co-pay, deductible and coinsurance), direct surgical costs, reimbursements and costto-charge ratios for OC and LC were compared using the Student's t-test and chisquare test where appropriate. RESULTS: OC and LC groups differed with respect to mean age (60 and 64 years, respectively; p < 0.001) but did not differ in male/ female ratio. OOP costs were significantly greater for OC ($410 vs. $350 for LC; p < 0.001). Both surgical costs and the reimbursements per case were significantly less for OC ($4231 ± 98 and $1412 ± 35, respectively) than LC ($5246 ± 231 and $1809 ± 80 respectively; both p < 0.001). Cost-to-charge ratios were the same for both surgical procedures (0.38). CONCLUSIONS: This analysis demonstrated that patient financial burden, as assessed by OOP costs, was moderately greater for open colectomy, but the direct costs and reimbursements of OC were significantly lower than LC. However, low surgical costs may be offset by potential increases in length of hospital stay due to longer recovery time for OC. Understanding differences in cost structures may be helpful in further investigations of the cost-effectiveness of these two surgical procedures in diverticular disease.
PGI11 PEDIATRIC HOSPITALIZATIONS FOR INFLAMMATORY BOWEL DISEASE: RESULTS FROM 2006 KIDS' INPATIENT DATABASE
Tundia N, Heaton PC, Kelton CM University of Cincinnati, Cincinnati, OH, USA OBJECTIVES: Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively termed Inflammatory Bowel Disease (IBD), are associated with hospitalizations, surgical procedures, and long-term medical follow up. The objectives of the current study were to quantify the national pediatric IBD burden in 2006 and stratify by demographics by determining the (1) number of hospitalizations; (2) number of days spent in the hospital; and (3) hospitalization costs. METHODS: The 2006 Kids' Inpatient Database was used to examine IBD in hospitalized children and adolescents 20 years and younger with a primary diagnosis of either CD or UC. Frequency of discharges, the total and mean length of stay (LOS) and costs were calculated, and stratified by various patient and hospital characteristics such as age, gender, expected primary payer, patient income, surgery status, teaching status, hospital size, location and region. RESULTS: In 2006, there were 10,777 IBD-related pediatric visits, of which 6,599 were due to CD and 4,178 were due to UC. For CD and UC, respectively, there were 37,175 and 27,810 days spent in the hospital; mean LOS was 5.63 and 6.66 days. The total and mean costs for CD were $66.3 million and $10,176, respectively. The total and mean costs for UC were $48.6 million and $11,836, respectively. For CD, 0-5 year old patients had the highest mean LOS (8.10 days) and mean cost ($13,894), while, for UC, 11-15-year old patients had the highest mean LOS (7.49 days) and mean cost ($13,407) . Patients with Medicaid had a higher mean LOS and cost than those with private insurance. Surgery increased mean LOS over 3 days and almost doubled the cost for IBD hospitalizations. CONCLUSIONS: IBD is a burdensome illness. Future research will determine if newer treatment options can reduce hospitalizations. 6 Mayo Clinic Jacksonville, FL, Rochester, MN, USA OBJECTIVES: Functional dyspepsia is a common, morbid condition but data are limited on the indirect and direct costs for employees with functional dyspepsia or on its impact on productivity. Few data on absenteeism no objective information are available. This study aimed to assess functional dyspepsia's incremental health benefit costs and effects on absenteeism and work output (productivity). METHODS: We performed a retrospective analysis of payroll data and adjudicated health insurance medical and prescription claims collected over a 4-year study period (January 1, 2001 -December 31, 2004 ) from more than 300,000 employees. Data from employees with and without (controls) functional dyspepsia were compared using 2-part regression techniques. Outcome measures included direct and indirect costs paid by the employer, absenteeism, direct costs by the place of service where care was performed, and objectively measured productivity output. RESULTS: Employees with functional dyspepsia (N = 1669) had greater average annual direct medical and prescription drug costs and indirect costs (due to sick leave, short-and long-term disability absences) than controls (N = 274,206). Compared with controls, the functional dyspepsia employees incurred health benefit costs that were $5,138 greater and had greater costs for each place of service (all P < 0.0001). The employees with functional dyspepsia had an additional 0.83 absence days per year and produced 12% fewer units per hour than controls (both P < 0.05). CONCLUSIONS: Employees with functional dyspepsia have greater costs at all places of service and lower productivity than employees without functional dyspepsia. HCV patients on PEG-RBV, untreated HCV, and non-HCV controls. We used propensity scores to match treated to untreated (1:1), and HCV to non-HCV patients (1:3). We compared direct costs and utilization across the cohorts. We performed subset analysis using the MarketScan Health and Productivity Management Database ® to evaluate absenteeism and shortterm disability costs. RESULTS: We identified 10,001 PEG-RBV patients. Compared to untreated patients, treated patients had higher total medical costs ($28,547 vs. $21,752; p < 0.001) outpatient pharmacy costs ($17,419 vs. $2,900; p < 0.001) and outpatient physician visit costs ($894 vs. $787; p < 0.001), but lower inpatient costs ($3,942 vs. $9,543; p < 0.001) and ER costs ($366 vs. $505; p < 0.001). Treated patients had similar absenteeism rates (93% vs. 88%; p = 0.27), higher short-term disability rates (33% vs. 30%;p < 0.001) and higher indirect costs ($11,528 vs. $9,316; p < 0.05). Non-HCV controls had significantly lower costs in all categories compared to patients with HCV. Total costs among matched non-HCV costs were $15,932, outpatient pharmacy costs were $1,796, outpatient physician visit costs were $429, inpatient costs were $2,181, and ER costs were $184; indirect costs were $7,654. After adjusting for demographic and clinical characteristics, including HIV and cirrhosis, differences remained significant but diminished. CONCLUSIONS: HCV patients engender a higher economic burden compared to non-HCV controls. Treated patients cost more than untreated patients; the cost differential is primarily driven by higher outpatient pharmacy costs. Indirect cost differences are driven by greater absenteeism duration and greater short term disability use and duration. These data provide insight into the economic burden of HCV and its treatment, and may be employed in future health economic analyses evaluating existing and emerging therapies.
PGI12 FUNCTIONAL DYSPEPSIA DECREASE PRODUCTIVITY AND INCREASED MEDICAL COSTS

PGI15 MEDICAL SERVICE UTILIZATION AND COSTS BY DISEASE SEVERITY, SUSTAINED VIRAL RESPONSE, AND GENOTYPE IN EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C VIRUS
Davis KL 1 , Mitra D 1 , Leteneux C 2 , Bapat B 1 , Naujoks C 2 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To document variations in resource utilization and costs by disease severity, sustained viral response (SVR), and genotype in a European population with chronic hepatitis C virus (C-HCV). METHODS: Patient charts from the UK, France, Germany, Spain, and Italy were retrospectively reviewed. Inclusion criteria were: C-HCV diagnosis within past 5 years; age ≥18 years; no diagnoses of hepatitis B or HIV/AIDS; ≥1 year follow-up post-diagnosis; no clinical trial participation. All-cause utilization and costs (2009 3) for hospitalizations, emergency room (ER) and office visits, and specialty referrals were aggregated within patients over 1 year post-diagnosis. C-HCV severity was assessed via Metavir score. Among patients receiving C-HCV-directed pharmacotherapy, SVR was defined by viral RNA < 10 IU/mL at ≥6 months post-treatment. Utilization and cost differences across clinical factors were assessed with multivariate modeling. RESULTS: In total, 1016 patients were identified. Overall, 23% of severe patients were hospitalized versus 2.5% of mild. Hospitalization was 5 times more likely in severe C-HCV compared to mild (odds ratio [OR] = 5.39; P = 0.008), while the hospitalization rate, measured by Poisson incidence rate ratio (IRR), was 4 times higher (IRR = 3.98; P = 0.010). Hospital costs were 31380 higher in severe versus mild disease (P = 0.001). Hospitalization risk in SVR attainers was less than half that of non-attainers (OR = 0.22; P < 0.0001). ER, office, and specialist visit rates were significantly lower among SVR attainers. Genotype had little effect on utilization, but genotype 1 was associated with slightly lower (390 per patient; P < 0.0001) hospital costs versus genotypes ≥2. CONCLUSIONS: Disease severity and SVR are important predictors of C-HCV costs. Awareness of these factors by public health systems, which bear the high cost burden of C-HCV, may help promote strategies for earlier disease detection and increased treatment initiation before progression occurs, as well as formulary access for more convenient therapies that increase treatment persistence and thereby SVR rates. A total of 92,804 patients with a diagnosis of CC or IBS were identified during the study period; 1873 filled at least one 30-day prescription for lubiprostone. Seventy-five percent of users were female. Lubiprostone users were younger than non-users (61.6 vs. 66.2 yrs old) and more likely to be co-prescribed opiates (35.5 vs. 29.4%), antihistamines (14.8 vs. 9.5%) and tricyclic antidepressants (8.1 vs. 4.7%), all statistically significant. Common co-morbidities in lubiprostone users were back problems (23.6%) and abdominal pain (21.9%). A total of 1605 users had both 6-months preand post-lubiprostone initiation data. A total of 42.2% of these patients filled more than one 30-day lubiprostone prescription; 6.42% filled 6 or more. Usage of other prescription laxatives decreased by 4.6% (p < 0.05) subsequent to lubiprostone initiation. Monthly health care costs per utilizing member increased by $67.10 (p < 0.0001). Pharmacy costs rose by $71.73 (p < 0.0001) and ER costs decreased by $8.12 (p < 0.05). Pre-post changes in outpatient and inpatient costs were not significant. Monthly inpatient and ER visits for these 1605 members decreased by 0.31 and 0.08 per utilizing member respectively (p < 0.05) in the 6-months after starting lubiprostone. Changes in outpatient visits were not significant. CONCLUSIONS: Lubiprostone users were younger females who were co-prescribed opiates and had back problems. Higher health care costs were offset by a decrease in ER costs. 3 Roche Brazil, São Paulo, Brazil Hepatitis C affects approximately 180 million people worldwide and is one of the main causes of chronic liver disease. HCV infection progresses to chronicity in approximately 80% of infected individuals, from whom up to 20% can develop cirrhosis over 20 years, thus presenting high risk of complications related to hepatic insufficiency and/or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated
PGI16 PATTERNS OF LUBIPROSTONE UTILIZATION AND COSTS IN MEMBERS OF A LARGE HEALTH BENEFITS COMPANY
PGI17 COST-EFFECTIVENESS ANALYSIS OF TREATMENT
